Oxidative Stress and Inflammation in Retinal Degeneration 2022

A special issue of Antioxidants (ISSN 2076-3921). This special issue belongs to the section "Health Outcomes of Antioxidants and Oxidative Stress".

Deadline for manuscript submissions: closed (31 May 2022) | Viewed by 3434

Special Issue Editors


E-Mail Website
Guest Editor
Professor of Biochemistry and Molecular Biology, Ophthalmology and Graduate Studies, Georgia Cancer Center and Culver Vision Discovery Institute, Medical College of Georgia at Augusta University, Augusta, GA, USA
Interests: retina; diabetes; diabetic retinopathy; microRNA; sickle cell retinopathy; age-related macular degeneration; retinal pigment epithelium
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department Biochemistry & Molecular Biology, The Medical College of Georgia at Augusta University, Augusta, GA 30912, USA
Interests: gut microbiome; liver diseases; aging; energy metabolism; natural compounds
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Our previous Special Issue on “Oxidative Stress and Inflammation in Retinal Degeneration” (https://www.mdpi.com/journal/antioxidants/special_issues/oxidative_stress_retinal_degeneration), published in the 2021 volume of Antioxidants, received an overwhelming number of submissions, and was  a successful compilation of research and review articles. As this a rapidly evolving topic in the field of vision science research and much remains to be learned, we would like to further explore the role of oxidative stress and inflammation in retinal degeneration with a follow-up Special Issue for the year 2022. Robust experimental evidence points to a prominent role of inflammation and oxidative stress in the pathogenesis of many degenerative diseases of the retina (e.g., age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, retinitis pigmentosa). This is supported by confirmatory studies conducted using human ocular tissues. The retina is consistently exposed to high levels of oxidative stress as a normal consequence of significant light exposure, visual signal transduction pathways that generate considerable amounts of reactive oxygen species, the oxidation of polyunsaturated fatty acids, etc. Normal healthy retinal cells do an excellent job of squelching pro-oxidant factors to maintain homeostasis. However, in aging and/or disease, the efficiency of these normal homeostatic mechanisms often declines, disrupting the balance between pro- and anti-oxidative signaling. This contributes to excessive oxidative stress, related inflammation, dysregulated immune responses, potential blood–retinal barrier compromise, and tissue damage. Thus, better understanding the mechanisms governing the cellular and molecular events that underlie the switch that precipitates the failure of the retina to respond adequately to oxidative and/or inflammatory insults, leaving the tissue susceptible to degenerative processes, may support the discovery of new therapeutic targets to prevent and treat irreversible vision loss and blindness. As such, this second Special Issue welcomes submissions of original research and review articles, commentaries, brief reports, and clinical trials related to any aspect of the role of oxidative stress and inflammation in pathogenic retinal degeneration, the identification and exploration of novel targets, and the development and testing of antioxidant and anti-inflammatory therapies.

Dr. Pamela M. Martin
Dr. Ravirajsinh N. Jadeja
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antioxidants is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • retinal degeneration
  • antioxidants
  • oxidative stress
  • age-related macular degeneration
  • retinal inflammation
  • therapeutic targets
  • aging retina

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 3624 KiB  
Article
Epoxomicin, a Selective Proteasome Inhibitor, Activates AIM2 Inflammasome in Human Retinal Pigment Epithelium Cells
by Iswariyaraja Sridevi Gurubaran, Maria Hytti, Kai Kaarniranta and Anu Kauppinen
Antioxidants 2022, 11(7), 1288; https://doi.org/10.3390/antiox11071288 - 28 Jun 2022
Cited by 3 | Viewed by 2766
Abstract
Emerging evidence suggests that the intracellular clearance system plays a vital role in maintaining homeostasis and in regulating oxidative stress and inflammation in retinal pigment epithelium (RPE) cells. Dysfunctional proteasomes and autophagy in RPE cells have been associated with the pathogenesis of age-related [...] Read more.
Emerging evidence suggests that the intracellular clearance system plays a vital role in maintaining homeostasis and in regulating oxidative stress and inflammation in retinal pigment epithelium (RPE) cells. Dysfunctional proteasomes and autophagy in RPE cells have been associated with the pathogenesis of age-related macular degeneration. We have previously shown that the inhibition of proteasomes using MG-132 activates the NLR family pyrin domain containing 3 (NLRP3) inflammasome in human RPE cells. However, MG-132 is a non-selective proteasome inhibitor. In this study, we used the selective proteasome inhibitor epoxomicin to study the effect of non-functional intracellular clearance systems on inflammasome activation. Our data show that epoxomicin-induced proteasome inhibition promoted both nicotinamide adenine dinucleotide phosphate oxidase and mitochondria-mediated oxidative stress and release of mitochondrial DNA to the cytosol, which resulted in potassium efflux-dependent absence in melanoma 2 (AIM2) inflammasome activation and subsequent interleukin-1β secretion in ARPE-19 cells. The non-specific proteasome inhibitor MG-132 activated both NLRP3 and AIM2 inflammasomes and oxidative stress predominated as the activation mechanism, but modest potassium efflux was also detected. Collectively, our data suggest that a selective proteasome inhibitor is a potent inflammasome activator in human RPE cells and emphasize the role of the AIM2 inflammasome in addition to the more commonly known NLRP3 inflammasome. Full article
(This article belongs to the Special Issue Oxidative Stress and Inflammation in Retinal Degeneration 2022)
Show Figures

Figure 1

Back to TopTop